deferoxamine has been researched along with Benign Neoplasms, Brain in 7 studies
Deferoxamine: Natural product isolated from Streptomyces pilosus. It forms iron complexes and is used as a chelating agent, particularly in the mesylate form.
desferrioxamine B : An acyclic desferrioxamine that is butanedioic acid in which one of the carboxy groups undergoes formal condensation with the primary amino group of N-(5-aminopentyl)-N-hydroxyacetamide and the second carboxy group undergoes formal condensation with the hydroxyamino group of N(1)-(5-aminopentyl)-N(1)-hydroxy-N(4)-[5-(hydroxyamino)pentyl]butanediamide. It is a siderophore native to Streptomyces pilosus biosynthesised by the DesABCD enzyme cluster as a high affinity Fe(III) chelator.
| Excerpt | Relevance | Reference |
|---|---|---|
| " 5-aminolevulinic acid (ALA) is metabolized to fluorescent protoporphyrin IX (PpIX) specifically in tumor cells, and therefore clinically used as a reagent for photodynamic diagnosis (PDD) and therapy (PDT) of cancers including gliomas." | 7.85 | Enhancement of 5-aminolevulinic acid-based fluorescence detection of side population-defined glioma stem cells by iron chelation. ( Hagiya, Y; Kokubu, Y; Murota, Y; Ogura, SI; Sugiyama, Y; Tabu, K; Taga, T; Wang, W, 2017) |
| "A phase II trial of a single 5-day course of deferoxamine in 9 patients with neuroblastomas was completed." | 7.68 | Effects of a single course of deferoxamine in neuroblastoma patients. ( Castello, MA; Deb, G; Dominici, C; Donfrancesco, A; Helson, L; Pileggi, D, 1990) |
| " 5-aminolevulinic acid (ALA) is metabolized to fluorescent protoporphyrin IX (PpIX) specifically in tumor cells, and therefore clinically used as a reagent for photodynamic diagnosis (PDD) and therapy (PDT) of cancers including gliomas." | 3.85 | Enhancement of 5-aminolevulinic acid-based fluorescence detection of side population-defined glioma stem cells by iron chelation. ( Hagiya, Y; Kokubu, Y; Murota, Y; Ogura, SI; Sugiyama, Y; Tabu, K; Taga, T; Wang, W, 2017) |
| "A phase II trial of a single 5-day course of deferoxamine in 9 patients with neuroblastomas was completed." | 3.68 | Effects of a single course of deferoxamine in neuroblastoma patients. ( Castello, MA; Deb, G; Dominici, C; Donfrancesco, A; Helson, L; Pileggi, D, 1990) |
| "Glioblastoma multiforme are highly invasive brain tumors." | 1.34 | Involvement of Hif-1 in desferrioxamine-induced invasion of glioblastoma cells. ( Elstner, A; Holtkamp, N; von Deimling, A, 2007) |
| "Deferoxamine is an effective iron chelator and a potential therapeutic agent for use in minimizing free radical-mediated injury following trauma." | 1.30 | Screening of transcriptionally regulated genes following iron chelation in human astrocytoma cells. ( Connor, JR; Ye, Z, 1999) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (42.86) | 18.2507 |
| 2000's | 2 (28.57) | 29.6817 |
| 2010's | 2 (28.57) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lo Dico, A | 1 |
| Valtorta, S | 1 |
| Martelli, C | 1 |
| Belloli, S | 1 |
| Gianelli, U | 1 |
| Tosi, D | 1 |
| Bosari, S | 1 |
| Degrassi, A | 1 |
| Russo, M | 1 |
| Raccagni, I | 1 |
| Lucignani, G | 1 |
| Moresco, RM | 1 |
| Ottobrini, L | 1 |
| Wang, W | 1 |
| Tabu, K | 1 |
| Hagiya, Y | 1 |
| Sugiyama, Y | 1 |
| Kokubu, Y | 1 |
| Murota, Y | 1 |
| Ogura, SI | 1 |
| Taga, T | 1 |
| Dayani, PN | 1 |
| Bishop, MC | 1 |
| Black, K | 1 |
| Zeltzer, PM | 1 |
| Elstner, A | 1 |
| Holtkamp, N | 1 |
| von Deimling, A | 1 |
| Philipov, P | 1 |
| Ye, Z | 1 |
| Connor, JR | 1 |
| Donfrancesco, A | 1 |
| Deb, G | 1 |
| Dominici, C | 1 |
| Pileggi, D | 1 |
| Castello, MA | 1 |
| Helson, L | 1 |
1 review available for deferoxamine and Benign Neoplasms, Brain
| Article | Year |
|---|---|
Desferoxamine (DFO)--mediated iron chelation: rationale for a novel approach to therapy for brain cancer.
Topics: Brain Neoplasms; Deferoxamine; Humans; Iron; Iron Chelating Agents | 2004 |
6 other studies available for deferoxamine and Benign Neoplasms, Brain
| Article | Year |
|---|---|
Validation of an engineered cell model for in vitro and in vivo HIF-1α evaluation by different imaging modalities.
Topics: Animals; Brain Neoplasms; Cell Hypoxia; Cell Line, Tumor; Cell Shape; Deferoxamine; Glioma; Humans; | 2014 |
Enhancement of 5-aminolevulinic acid-based fluorescence detection of side population-defined glioma stem cells by iron chelation.
Topics: Aminolevulinic Acid; Animals; ATP Binding Cassette Transporter, Subfamily G, Member 2; Biotransforma | 2017 |
Involvement of Hif-1 in desferrioxamine-induced invasion of glioblastoma cells.
Topics: Blotting, Western; Brain Neoplasms; Cell Line, Tumor; Cell Separation; Deferoxamine; Flow Cytometry; | 2007 |
Suppression of tumor growth in experimental 9L gliosarcoma model by copper depletion.
Topics: Brain Neoplasms; Chelating Agents; Deferoxamine; Glioma; Humans; Penicillamine; Trace Elements | 1996 |
Screening of transcriptionally regulated genes following iron chelation in human astrocytoma cells.
Topics: Astrocytoma; Brain Neoplasms; Chelating Agents; Deferoxamine; Gene Expression Regulation, Neoplastic | 1999 |
Effects of a single course of deferoxamine in neuroblastoma patients.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Child; Child, Preschool | 1990 |